Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 15;18:11779322241287115. doi: 10.1177/11779322241287115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — (A) (left) Incidence of CC factor alterations in different types of bowel cancers in cohort of patients with APC mutations (4393 patients). Key: as in Figure 1B. (right) Progression-free survival (905 patients; q = 1.160e-4) of patients with APC mutations. Blue line represents unaltered group (patients with APC mutations and without alterations in any CC factor) and red line represents patients with APC mutations and with at least 1 alteration in the 6 queried CC genes. (B) (left) Incidence of CC alterations in bowel cancers in patients with KRAS mutations (2737 patients). (right) Progression-free survival (555 patients, q = 2.191e-3) of patients with KRAS mutations. Blue line represents unaltered group (patients with KRAS mutations but without alterations in any CC factor) and red line represents patients with KRAS mutations and with at least 1 alteration in the 6 queried CC genes. (C) (left) Incidence of CC alterations in bowel cancers in patients with TP53 mutations (4275 patients). (right) Progression-free survival (775 patients, q = 5.970e-3) of patients with TP53 mutations. Blue line represents unaltered group (patients with TP53 mutations but without alterations in any CC factor) and red line represents patients with TP53 mutations and with at least 1 alteration in the 6 queried CC genes. (D) (left) Incidence of CC alterations in bowel cancers in patients with BRAF mutations (661 patients). (middle) Progression-free (185 patients, q = 1.319e-6) and (right) overall survival (310 patients, q = 1.204e-4) of patients with BRAF mutations. Blue line represents unaltered group (patients with BRAF mutations but without alterations in any CC factor) and red line represents patients with BRAF mutations and with at least 1 alteration in the 6 queried CC genes. (E) Incidence of CC alterations in bowel cancers of patients with BRAF mutations from PanCancer Atlas dataset (62 patients). Key: as in Figure 1B.